Morepen Laboratories Ltd is an Indian pharmaceutical company that makes medicines, healthcare products, and chemicals. It was started in 1984 and is based in Himachal Pradesh. The company is known for making medicines for diabetes, heart problems, and infections. It also makes health products like blood pressure monitors and thermometers.
Morepen is famous for producing Montelukast, a medicine used for asthma and allergies. It also makes ingredients for medicines that are sold in India and other countries. The company focuses on good quality and affordable healthcare for everyone.
Morepen Laboratories Share Price Target (2025-2030)
| Year | Target Price Range (₹) |
|---|---|
| 2025 | ₹55.32 to ₹74.89 |
| 2026 | ₹75.15 to ₹84.67 |
| 2027 | ₹95.78 to ₹110.42 |
| 2028 | ₹115.23 to ₹130.96 |
| 2029 | ₹135.55 to ₹150.88 |
| 2030 | ₹160.11 to ₹175.73 |
Morepen Laboratories Share Price Target 2025
The Morepen Laboratories Share Price Target for 2025 is expected to be ₹55.32 to ₹74.89. This means the share price may increase based on the company’s current performance, steady earnings, and investor interest in the pharma industry.
Morepen Laboratories Share Price Target 2026
The target price is expected to be ₹75.15 to ₹84.67. The stock may rise as the company sells more products, introduces new medicines, and expands its market.
Morepen Laboratories Share Price Target 2027
By 2027, the Morepen Laboratories Share Price Target may reach ₹95.78 to ₹110.42. Increasing demand for pharmaceutical and healthcare products, along with strategic expansions, could boost investor confidence.
Morepen Laboratories Share Price Target 2028
For 2028, the Morepen Laboratories Share Price Target is expected to be ₹115.23 to ₹130.96. The company’s strong financials, research advancements, and potential international growth may contribute to this rise.
Morepen Laboratories Share Price Target 2029
By 2029, the Morepen Laboratories Share Price Target could increase to ₹135.55 to ₹150.88, reflecting the company’s long-term profitability, lower debt levels, and sustained demand for its products.
Morepen Laboratories Share Price Target 2030
Looking ahead to 2030, the Morepen Laboratories Share Price Target is estimated to be ₹160.11 to ₹175.73. If the company maintains consistent revenue growth, product expansion, and strong investor interest, this target range could be realistic.
Morepen Laboratories Ltd Fundamental
| Metric | Value |
|---|---|
| Market Cap | ₹2,468 Cr |
| P/E Ratio (TTM) | 19.58 |
| P/B Ratio | 2.22 |
| Industry P/E | 32.37 |
| Debt to Equity | 0.03 |
| ROE (Return on Equity) | 11.82% |
| EPS (TTM) | 2.30 |
| Dividend Yield | 0.00% |
| Book Value | 20.27 |
| Face Value | 2 |
Morepen Laboratories Ltd Income Statement (Dec 2024)
| Particulars | Dec ‘2024 |
|---|---|
| Revenue | ₹408.12 Cr |
| Expenses | ₹377.76 Cr |
| EBITDA | ₹36.45 Cr |
| EBIT | ₹31.65 Cr |
| Profit Before Tax | ₹30.38 Cr |
| Net Profit | ₹22.69 Cr |
Financial Ratios (Dec 2024)
| Ratio | Dec ‘2024 |
|---|---|
| Operating Profit Margin | 9.04% |
| Net Profit Margin | 5.63% |
| Earnings Per Share (Diluted) | ₹0.41 |
| Dividends Per Share | ₹0.00 |
Read More: Vaishali Pharma Share Price Target
Morepen Laboratories Ltd Balance Sheet (2024)
| Particulars | 2024 |
|---|---|
| Total Assets | ₹1,293 Cr |
| Current Assets | ₹889.04 Cr |
| Non-Current Assets | ₹404.16 Cr |
| Total Liabilities | ₹445.98 Cr |
| Current Liabilities | ₹402.04 Cr |
| Non-Current Liabilities | ₹43.93 Cr |
| Total Equity | ₹847.23 Cr |
| Common Stock | ₹102.23 Cr |
| Preferred Stock | ₹0.00 Cr |
| Other Equity Total | ₹745.00 Cr |
| Total Common Shares Outstanding | 51.12 Cr |
| Debt to Equity Ratio | 0.03 |
| Book Value | ₹16.58 |
Morepen Laboratories Ltd Shareholding Pattern (Dec 2024)
| Category | Holding (%) |
|---|---|
| Retail and Others | 60.48% |
| Promoters | 35.65% |
| Foreign Institutions | 2.22% |
| Other Domestic Institutions | 1.64% |
Conclusion
Morepen Laboratories Ltd is a financially stable and growing pharmaceutical company with a strong market presence. Its low debt, steady revenue growth, and expanding product portfolio indicate a positive outlook for the coming years. The share price targets suggest gradual appreciation, driven by increasing demand for medicines, healthcare products, and international expansion.
FAQ
What are the key products of Morepen Laboratories?
The company produces medicines for diabetes, heart problems, infections, asthma, and allergies. It is well known for manufacturing Montelukast, a medicine used to treat asthma and allergies. It also makes blood pressure monitors, thermometers, and other healthcare products.
Does Morepen Laboratories pay dividends?
Currently, Morepen Laboratories has a dividend yield of 0.00%, meaning it does not pay dividends. Investors benefit mainly through capital appreciation.
Is Morepen Laboratories a debt-free company?
No, but Morepen Laboratories has very low debt. Its Debt-to-Equity Ratio is 0.03, meaning it has almost no financial burden compared to other companies in the pharmaceutical sector.
Is Morepen Laboratories a multibagger stock?
A multibagger stock is one that gives high returns over time. Morepen Laboratories has shown consistent growth, but whether it becomes a multibagger depends on future earnings, expansion, and investor sentiment.
